MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

To determine whether a punctuated six-month course of ARV therapy during treatment of active TB will delay HIV disease progression, as measured by time until CD4+ count falls below 250 cells/µL, the ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

This is a preview. Log in through your library . Abstract Background. The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need ...

In a landmark moment for the fight against AIDS, a breakthrough study finds that antiretroviral therapy (ART) stops the spread of HIV. “What this study really shows is that risk of transmission is ...

Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people living with HIV, with no adverse impact on viral load or CD4 counts.

This transcript has been edited for clarity. Michael Saag, MD: Hello. I'm Dr Michael Saag, and welcome to Medscape InDiscussion: HIV. Today we're talking about antiretroviral therapy, maintenance, and ...